Compare Citius Pharmaceuticals Inc (CTXR) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Illinois Tool Works Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Illinois Tool Works Inc. trades at $275.91 (market cap $78.33B). The key difference: Illinois Tool Works Inc. is far larger — about 5350.4× Citius Pharmaceuticals Inc's market cap, and Illinois Tool Works Inc. pays a 2.37% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | ITW | |
|---|---|---|
Market Cap | $14.64M | $78.33B |
Sector | Health | Industrials |
52-Week High | $1.82 | $299.60 |
52-Week Low | $0.53 | $241.07 |
Enterprise Value | $10.86M | $86.66B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Illinois Tool Works (ITW) trades at $271.50, up 1.0% today, with a bullish technical signal from moving averages and a consensus analyst price target of $288.25. The company has consistently beaten earnings estimates in recent quarters, including Q1 2026 EPS of $2.66 versus $2.57 expected, and maintains strong profitability with a net income margin of 19.32% and ROE of 96.88%. Recent news highlights segment strength and a declared quarterly dividend of $1.61.
The outlook for ITW is positive, supported by earnings momentum and operational efficiency, though risks include construction sector weakness and currency headwinds. The stock offers a balanced opportunity with solid fundamentals and a dividend, but investors should weigh high valuation multiples against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
